Retatrutide, a groundbreaking dual-acting glucose-regulated incretin agent, represents a significant advance in peptide medicines for the treatment of type 2 diabetes and, increasingly, obesity. Unlike many existing treatment interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor activator, offering a more comp